These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 32951235)
1. Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era. Ciotti JR; Grebenciucova E; Moss BP; Newsome SD Ann Neurol; 2020 Dec; 88(6):1062-1064. PubMed ID: 32951235 [No Abstract] [Full Text] [Related]
2. The COVID-19 pandemic and the use of MS disease-modifying therapies. Giovannoni G; Hawkes C; Lechner-Scott J; Levy M; Waubant E; Gold J Mult Scler Relat Disord; 2020 Apr; 39():102073. PubMed ID: 32334820 [No Abstract] [Full Text] [Related]
3. COVID-19 will change MS care forever - No. Preziosa P; Rocca MA; Filippi M Mult Scler; 2020 Sep; 26(10):1149-1151. PubMed ID: 32567471 [No Abstract] [Full Text] [Related]
4. COVID-19 and the newly rediscovered multidisciplinarity. Bersanelli M Immunotherapy; 2020 Oct; 12(15):1101-1103. PubMed ID: 32957828 [No Abstract] [Full Text] [Related]
5. Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection? Ghajarzadeh M; Bonavita S Neurol Sci; 2020 Sep; 41(9):2315-2316. PubMed ID: 32638135 [No Abstract] [Full Text] [Related]
6. Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Sastre-Garriga J; Tintoré M; Montalban X Mult Scler; 2020 Sep; 26(10):1153-1156. PubMed ID: 32552382 [No Abstract] [Full Text] [Related]
8. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity. Goudsmit J Eur J Epidemiol; 2020 Apr; 35(4):331-333. PubMed ID: 32318914 [No Abstract] [Full Text] [Related]
9. COVID-19 will change MS care forever - Yes. Meca-Lallana V Mult Scler; 2020 Sep; 26(10):1147-1148. PubMed ID: 32567486 [No Abstract] [Full Text] [Related]
10. Is Gradual and Controlled Approach to Herd Protection a Valid Strategy to Curb the COVID-19 Pandemic? Laxminarayan R; John TJ Indian Pediatr; 2020 Jun; 57(6):505-507. PubMed ID: 32376793 [No Abstract] [Full Text] [Related]
11. Rehabilitation Recommendations for Multiple Sclerosis Patients during the COVID-19 Pandemic. Naser Moghadasi A; Azadvari M; Sahraian MA Arch Iran Med; 2020 Jul; 23(7):509-510. PubMed ID: 32657605 [No Abstract] [Full Text] [Related]
14. Developing Covid-19 Vaccines at Pandemic Speed. Lurie N; Saville M; Hatchett R; Halton J N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757 [No Abstract] [Full Text] [Related]
15. Do pets protect their owners in the COVID-19 era? Jurgiel J; Filipiak KJ; Szarpak Ł; Jaguszewski M; Smereka J; Dzieciątkowski T Med Hypotheses; 2020 Sep; 142():109831. PubMed ID: 32428810 [No Abstract] [Full Text] [Related]
16. Keeping track of the SARS-CoV-2 vaccine pipeline. Parker EPK; Shrotri M; Kampmann B Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290 [TBL] [Abstract][Full Text] [Related]
17. COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile. Ciampi E; Uribe-San-Martin R; Cárcamo C Mult Scler Relat Disord; 2020 Jul; 42():102204. PubMed ID: 32570203 [No Abstract] [Full Text] [Related]
18. Riding the coronacoaster of uncertainty. The Lancet Infectious Diseases Lancet Infect Dis; 2020 Jun; 20(6):629. PubMed ID: 32422202 [No Abstract] [Full Text] [Related]